About: Characteristics and outcomes of asthmatic patients with COVID-19 pneumonia who require hospitalisation

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Characteristics and outcomes of asthmatic patients with COVID-19 pneumonia who require hospitalisation Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Characteristics and outcomes of asthmatic patients with COVID-19 pneumonia who require hospitalisation
Creator	Duranteau, Jacques Richard, Christian Humbert, Marc Bellin, Marie-France Monnet, Xavier Montani, David Parent, Florence Pichon, Jérémie Savale, Laurent Beurnier, Antoine Boucly, Athénaïs Bulifon, Sophie Chaumais, Marie-Camille Frank, Marie Harrois, Anatole Jaïs, Xavier Jevnikar, Mitja Jutant, Etienne-Marie Laurent, Jérémy Noël, Nicolas Preda, Mariana Seferian, Andrei Sitbon, Olivier Humbert, Pr
source	Medline; PMC
abstract	BACKGROUND: Viral respiratory infections are the main causes of asthma exacerbation. The susceptibility of asthmatics to develop an exacerbation when they present with severe pneumonia due to SARS-CoV-2 infection is unknown. The objective of this study was to investigate the characteristics and outcomes of asthmatic patients with COVID-19 pneumonia who required hospitalisation during the spring 2020 outbreak in Paris, France. METHODS: A prospective cohort follow-up was carried out from March 15 to April 15, 2020 in Bicêtre Hospital, University Paris-Saclay, France. All hospitalised patients with a SARS-CoV-2 infection who reported a history of asthma were included. RESULTS: Among 768 hospitalised patients, 37 (4.8%) reported a history of asthma, which had been previously confirmed by a pulmonologist in 85% of cases. Patients were mainly female (70%), non-smokers (85%), with a median age of 54 years (interquartile range, IQR 42–67). None of them presented with an asthma exacerbation. Twenty-two (59%) had major comorbidities and 31 (84%) had a body mass index ≥25 kg·m(−2). The most common comorbidities were obesity (36%), hypertension (27%) and diabetes (19%). All patients had a confirmed diagnosis of COVID-19 pneumonia on computed tomography of the chest. Eosinopenia was a typical biologic feature with a median count of 0/mm3 (IQR 0–0). Eleven patients (30%) were admitted in intensive care unit with three death (8.1%) occurring in the context of comorbidities. CONCLUSION: Asthmatics were not overrepresented among patients with severe pneumonia due to SARS-CoV-2 infection who required hospitalisation. Worst outcomes were observed mainly in patients with major comorbidities.
has issue date	2020-07-30(xsd:dateTime)
bibo:doi	10.1183/13993003.01875-2020
bibo:pmid	32732333
has license	cc-by-nc
sha1sum (hex)	d123689685dc1c5735e0cb8fce7af0dc4c01bb65
schema:url	https://doi.org/10.1183/13993003.01875-2020
resource representing a document's title	Characteristics and outcomes of asthmatic patients with COVID-19 pneumonia who require hospitalisation
has PubMed Central identifier	PMC7397950
has PubMed identifier	32732333
schema:publication	Eur Respir J
resource representing a document's body	covid:d123689685dc1c5735e0cb8fce7af0dc4c01bb65#body_text
is schema:about of	named entity 'hospitalization' named entity 'pneumonia' covid:arg/d123689685dc1c5735e0cb8fce7af0dc4c01bb65 named entity 'pulmonologist' named entity 'COVID-19' named entity 'omalizumab' named entity 'asthma exacerbation' named entity 'COVID' named entity 'asthmatic' named entity 'follow-up' named entity 'asthma' named entity 'asthmatic' named entity 'emergency department' named entity 'oxygen' named entity 'creatine phosphokinase' named entity 'BMI' named entity 'asthma' named entity 'asthma' named entity 'SARS-CoV-2' named entity 'CRP' named entity 'SARS-CoV' named entity 'asthmatics' named entity 'asthmatics' named entity 'COVID' named entity 'ground glass opacities' named entity 'COVID' named entity 'asthmatic' named entity 'asthma' named entity 'asthma attack' named entity 'COVID' named entity 'control group' named entity 'inhaled corticosteroids' named entity 'diabetes' named entity 'asthmatic' named entity 'SARS-CoV-2' named entity 'sex ratio' named entity 'bronchospasm' named entity 'D-dimers' named entity 'CRP' named entity 'ACE2' named entity 'smokers' named entity 'hypertension' named entity 'IL-6' named entity 'refractory' named entity 'COVID' named entity '85%' named entity 'France' named entity 'COVID' named entity 'SARS-CoV-2' named entity 'control group' named entity 'COVID' named entity 'subcutaneous' named entity 'IL-5' named entity 'biologics' named entity 'asthma' named entity 'hypocapnia' named entity 'smokers' named entity 'overdiagnosed'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software